spleectomy is less frequently applied as a second-line treatment, since the availability of effective pharmaceutical agents, the potential complications of splenectomy and the inability to predict on whether patients do respond to splenectomy. After several ITP treatment have been applied with no or only minimal response the diagnosis of ITP has to be reconsidered. In this case the presence of bone marrow failure syndromes, myelodysplastic syndrome or inherited thrombocytopenias must be excluded.\textsuperscript{2}

Learning Objectives

\begin{itemize}
\item Explain the pathophysiology of ITP
\item Describe how to make the diagnosis of ITP and when to reconsider diagnosis
\item Discuss the therapeutic options for refractory ITP
\end{itemize}

REFERENCES


\section{LESSONS FROM SCLERODERMA: TREATMENT OF INTERSTITITAL LUNG DISEASE IN SLE}

Oliver Distler. University Hospital Zürich, Switzerland

10.1136/lupus-2021-la.9

Interstitial lung diseases (ILDs) are frequent in systemic sclerosis (SSc) and affect approximately 50% of the patients during their disease course. SSc-ILD shows overlapping pathogenesis and clinical features with ILDs from other CTDs including SLE. In SSc, SSc-ILD is the most frequent cause of death, not only affecting patients with diffuse cutaneous SSc, but also with limited cutaneous SSc. In recent years, there have been breakthroughs in the treatment of SSc-ILD. This presentation will be based on a recent interdisciplinary consensus paper using state of the art consensus methodology to reach statements on treatments and other aspects of SSc-ILD.\textsuperscript{1} Level of evidence for the different treatment options will be discussed. Specifically, first line treatment recommendations include cyclophosphamide, mycophenylate mofetil and nintedanib.\textsuperscript{2} Second line treatments include rituximab, stem cell transplantation and early listing for lung transplantation, if appropriate. In addition, a very recent published Phase 3 trial point to efficacy of tocilizumab in patients with inflammatory, early, diffuse, and recently skin-progressive SSc-ILD.\textsuperscript{3} Open questions remain about the sequence of therapy selection, combination therapy, step up or step down combination therapy and personalised medicine in a very heterogeneous patient population.

Learning Objectives

\begin{itemize}
\item Explain the heterogeneity of ILDs in both pathophysiology and clinical course
\item Apply assessment of evidence level to clinical studies in ILDs
\item Describe the new treatment options and the need for individualized treatments of SSc-ILD
\item Discuss open questions and unmet needs in the ILDs
\end{itemize}

REFERENCES


\section{LESSONS FROM RA: RA DRUG DEVELOPMENT HAS ADVANCED AT A MORE RAPID PACE THAN SLE: WHAT CAN WE LEARN FROM OUR COLLEAGUES?}

Ronald van Vollenhoven. Amsterdam University Medical Centers, The Netherlands

10.1136/lupus-2021-la.10

In a little over two decades, the treatment of rheumatoid arthritis (RA) has changed dramatically. Nine different biologicals, with five different modes of action, and a new class of targeted synthetic medications have been approved and are being used in the care of millions of patients, and long-term outcomes have improved considerably. What factors have contributed to this unprecedented success, and can similar results be obtained in the treatment of systemic lupus erythematosus (SLE)? The following key ingredients of the RA success story will be discussed.

1. Clinical and structural outcomes for RA were intensively studied and accurately defined before the key clinical trials were launched.
2. Industry-sponsored and investigator-initiated clinical trials, often running in parallel, delivered complementary knowledge and insights.
3. Once approved, rheumatologists and their patients embraced the new developments, testing the possibilities and gathering data in registries, rapidly acquiring extensive practical experience.

I will discuss how similar approaches can be implemented in the development of new therapies for SLE. Although progress in this disease has been slow in coming, I will argue that the main conditions have now been fulfilled to accomplish significant beneficial changes in lupus therapeutics in the coming years.

Learning Objectives

\begin{itemize}
\item Describe why defining clinical and structural outcomes in RA was important to assessing benefit of novel treatments
\item Discuss advances in RA treatment and how drivers of successful treatment can be applied to treating SLE
\item Explain how practical experiences with novel treatments in RA have benefited patients and how similar experiences may benefit patients with SLE
\end{itemize}

Keynote

\section{KIDNEY BIOPSIES IN SLE: TOO FEW OR TOO MANY?}

Hans-Joachim Anders, LMU University Hospital, Munich, Germany

10.1136/lupus-2021-la.11

Kidney biopsy represents the gold standard for the diagnosis of lupus nephritis (LN) and is used to stratify patients for
the various therapy options. Kidney biopsy is a mandatory for LN trials, as a gold standard for biomarker studies, and for research on pathophysiology. However, can the initial biopsy really tell us anything about the immunopathogenesis of lupus in spleen and lymph nodes or about which drugs to choose or if the patient will respond to an adequate therapy? Will the recent discovery of EXT1/EXT2 deposits in about 1/3 of patients with Class V LN help to define subgroups of patients with unique phenotypes and prognosis? Isn’t the scientific attention to a biopsy that confirms the diagnosis and grossly defines intensity of treatment a bit irrational?

Too few kidney biopsies? Serum and urine biomarkers are used to guide immunosuppressive treatment of lupus nephritis, although there is compelling evidence that they poorly indicate persistent LN even in patients with a complete clinical response. The same problem in kidney allograft recipients is addressed by protocol biopsies, why is this not so in LN? A repeat biopsy at 12 months may be of utmost value to guide treatment and to predict long-term prognosis, something the first diagnostic biopsy hardly can do. The REBLUP trial will address this question. Other important repeat biopsy indications are the ‘partial responder biopsy’, the ‘smoldering lupus nephritis biopsy’, the ‘chronic kidney disease progression biopsy’ and the ‘drug withdrawal biopsy’.

Too many kidney biopsies? The least useful re-biopsy maybe when the patient flares as flare biopsies in patients with a previous Class III-V hardly ever affect treatment decisions. When patients with LN ‘flare’, drug non-adherence or recent reductions in drug doses are the most common cause, rather than a switch of the underlying disease. Systemic lupus erythematosus (SLE) is chronic autoimmune disease with continued disease activity, albeit at different levels in different patients. Therefore, LN does not require ‘induction’ and ‘maintenance’ therapy, but a constant long-term treatment usually with a combination of immunosuppressive drugs. SLE is heterogeneous across individuals but not within an individual. Repeat biopsies are needed to detect inflammation when you are not sure about it, not when it is obvious.

Learning Objectives
• Explain the importance of not overestimating the potential of the first diagnostic biopsy as a source of insights into pathophysiology and predictive power beyond what is known
• Describe the value of treatment response as the main predictor for outcome and the potential use of a protocol biopsy at 1 year in this context because serum and urine markers are unreliable
• Discuss and question the value of a ‘flare repeat biopsy’, because it rarely affects treatment decisions
• Discuss the use of repeat biopsies in non- or partial responders, smoldering lupus nephritis, CKD progression and before drug withdrawal
• Explain the important concept that SLE is a chronic autoimmune disease that requires constant long-term treatment usually with a drug combination (not transient ‘induction and maintenance therapy’ with single drugs), identical to how we control persistent alloimmunity in kidney transplant recipients

Debate: In with the new, out with old?
Should all patients with lupus nephritis receive new generation therapies in addition to established standard of care?

ALL LUPUS NEPHRITIS PATIENTS SHOULD BE INITIALLY MANAGED WITH BOTH ESTABLISHED STANDARD THERAPIES AND THE NEW GENERATION DRUGS

YK Onno Teng. Leiden University Medical Center (LUMC), the Netherlands
10.1136/lupus-2021-la.12

The year 2020 has been an extraordinary year in many ways but especially for patients with lupus nephritis (LN), as 2020 saw two novel agents (belimumab and voclosporin) finding FDA-approval for the treatment of LN. These agents will both enrich the therapeutic armamentarium, allowing physicians to better treat their LN patients, as well as broaden treatment strategies that can be employed.

In this pro-con debate, I will highlight the trial data that have led to the FDA approval of belimumab and voclosporin for the treatment of LN. I will also address the unmet needs these new compounds can address in the treatment of LN. Lastly, the potential treatment strategies emerging from the approval of these new agents will be addressed.

Learning Objectives
• Describe the evidence for the latest FDA-approved drugs for LN: Belimumab and voclosporin
• Describe the current challenges physicians face when treating patients with LN
• Describe possible new treatment strategies for patients with LN

ALL LUPUS NEPHRITIS PATIENTS SHOULD BE INITIALLY MANAGED WITH ESTABLISHED STANDARD THERAPIES ALONE

Dimitrios Boumpas. National and Kapodistrian University of Athens, Greece
10.1136/lupus-2021-la.13

Lupus nephritis (LN) is extremely heterogeneous with most patients responding to standard immunosuppressive therapy within 6–12 months. Post hoc analyses suggest that proteinuria at 12 months represents the best single predictor for long-term renal outcome (i.e., risk for end-stage kidney disease (ESKD) or doubling of serum creatine after 10 years). Accordingly, therapy should aim for proteinuria reduction to below 0.7 gm-1/day by 12 months (complete renal response) with patients with nephrotic range proteinuria reaching this milestone for later, by approximately 24 months. Even patients without a complete response at 12–24 months (defined as proteinuria below 1 gm/day and stable creatinine) have an excellent 10-year prognosis.

Based on the above, rushing into using novel therapies from the beginning has the risk of overtreating the vast majority of patients. This is especially true for patients that receive